Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Gross Margin (2016 - 2019)

Historic Gross Margin for Aptevo Therapeutics (APVO) over the last 5 years, with Q4 2019 value amounting to 32.06%.

  • Aptevo Therapeutics' Gross Margin changed N/A to 32.06% in Q4 2019 from the same period last year, while for Dec 2019 it was 38.54%, marking a year-over-year change of. This contributed to the annual value of 38.54% for FY2019, which is 128400.0% down from last year.
  • Per Aptevo Therapeutics' latest filing, its Gross Margin stood at 32.06% for Q4 2019.
  • Aptevo Therapeutics' Gross Margin's 5-year high stood at 77.22% during Q1 2017, with a 5-year trough of 67.24% in Q2 2017.
  • For the 5-year period, Aptevo Therapeutics' Gross Margin averaged around 36.33%, with its median value being 45.22% (2019).
  • In the last 5 years, Aptevo Therapeutics' Gross Margin crashed by -1030400bps in 2017 and then surged by 1301200bps in 2018.
  • Aptevo Therapeutics' Gross Margin (Quarter) stood at 36.8% in 2015, then grew by 14bps to 42.07% in 2016, then skyrocketed by 66bps to 69.67% in 2017, then decreased by -17bps to 58.16% in 2018, then crashed by -45bps to 32.06% in 2019.
  • Its Gross Margin stands at 32.06% for Q4 2019, versus 56.06% for Q3 2019 and 18.68% for Q2 2019.